🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against superbug strains of the infection, according to researchers.

An International Public Health Issue

The sexually transmitted infection are on the rise around the world, with data suggesting in excess of 82 million instances each year. Especially elevated rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, the spread of superbugs and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers hope that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to bring it to fruition.

“This authorization marks a significant shift in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

According to findings detailed in a major medical journal, the new drug successfully treated the vast majority of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which combines an injection and a pill. The research included hundreds of volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared optimism. The availability of a one-pill regimen of this kind is described as a "critical tool" for public health efforts. This is deemed essential to reduce the burden of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.